ZOMDF Zomedica Corp.

CIK 0001684144 19 ready 8-Ks latest May 6, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 0 baseline

Ready 8-Ks 19

Latest filing May 6, 2026, 7:59 PM ET

Top materiality 0.75

Event mix earnings ×10 · leadership ×3 · other_material ×3

Sentiment 5 pos · 6 neg · 8 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for ZOMDF

Highest-materiality recent filing

Zomedica reports record Q4 revenue $10.5M, full-year revenue $32.0M (+17% YoY)

March 16, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Q4 revenue $10.5M (+33% YoY); full year $32.0M (+17%). Record 20th straight YoY increase.
Gross margin 68% for year; Q4 69% best quarter. Adjusted EBITDA loss improved to $17.1M from $20.2M.

Read filing →

May 6, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Zomedica Q1 revenue record $8.8M, up 35% YoY; net loss narrows to $4.5M

Record Q1 revenue $8.8M, up 35% from $6.5M in Q1 2025; 21st straight quarter of YoY growth.
March 16, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Zomedica reports record Q4 revenue $10.5M, full-year revenue $32.0M (+17% YoY)

Q4 revenue $10.5M (+33% YoY); full year $32.0M (+17%). Record 20th straight YoY increase.
November 4, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Zomedica Q3 2025 revenue $8.1M (+16% YoY); net loss narrows to $6.1M

Revenue $8.1M, up 16% YoY; gross margin 67%; Diagnostics segment grew 51%.
August 6, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Zomedica Q2 revenue up 14% to $7M; Diagnostics segment jumps 86%

Revenue $7.0M, up 14% YoY; gross margin 67%, consistent with prior period.
May 15, 2025, 7:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01

Zomedica Q1 revenue $6.5M (+4% YoY), net loss $63.8M on $55.8M impairment

Revenue $6.5M (+4% YoY); gross margin 68% vs 66% in Q1 2024.
April 30, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change ×2

CFO Scott Jordan resigns; VP Finance Michael Zuehlke assumes interim role

Scott Jordan resigned as CFO effective April 25, 2025; receives $80,769 lump sum and 3 months COBRA reimbursement.
March 5, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 item 9.01

Zomedica delisted from NYSE American, to trade on OTCQB starting March 5 under ZOMDF

NYSE American suspended trading March 4, 2025 due to low share price under Section 1003(f)(v).
December 19, 2024, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 item 9.01

Zomedica appoints Scott Jordan as CFO effective Jan 1, 2025; base salary $350K plus options

Scott Jordan appointed Executive VP Finance and CFO, effective January 1, 2025.
November 8, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Zomedica Q3 revenue up 10% to $7.0M; gross margin 72.3%; diagnostics segment grows 38%

Revenue $7.0M (+10% YoY); gross margin 72.3% above 65-70% guidance.
August 14, 2024, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 9.01

Zomedica CFO Peter Donato resigns; VP Finance Zuehlke steps in as interim

CFO Peter Donato resigned effective Aug 15, 2024; enters 3-year consulting agreement for transition.
August 14, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Zomedica reports record FY2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY2024 $31-35M

Q4 2023 revenue $7.3M (+19% YoY); FY2023 revenue $25.2M (+33% YoY), driven by Diagnostics (+252%) and Therapeutic Devices (+28%).
May 9, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Zomedica Q1 revenue up 14% to $6.3M, net loss widens to $9.2M; FY guidance reaffirmed

Q1 2024 revenue $6.3M (+14% YoY) driven by 86% growth in Diagnostics and 9% in Therapeutic Devices.
April 4, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases ×3

Zomedica reports record FY 2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY 2024 revenue $31-35M

Q4 2023 revenue $7.3M (+19% YoY); full-year revenue $25.2M vs $18.9M in 2022.
March 15, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Zomedica continues NYSE American listing dialogue after shareholder rejection of reverse split

Received NYSE American deficiency letter Sept 2023 for 30-day avg share price below $0.20 per Section 1003(f)(v).
February 29, 2024, 6:59 PM ET other material materiality 0.70 negative item 5.07 ◈ Shareholder Votes

Zomedica shareholders reject 80-for-1 reverse stock split at special meeting

Share Consolidation Proposal required two-thirds approval; received only 39.44% 'for' votes.

Executive changes

Appointed (interim)

Michael Zuehlke

Vice President of Finance and Corporate Controller

ZOMDF · Zomedica Corp.

Filed: April 30, 2025, 7:59 PM ET

Until a Chief Financial Officer is hired to replace Mr. Jordan, Mr. Michael Zuehlke, Vice President of Finance and Corporate Controller of Zomedica Inc. will assume operational responsibility for accounting and finance matters.

Departed

Scott Jordan

Chief Financial Officer

ZOMDF · Zomedica Corp.

Effective: 2025-04-25
Successor: Michael Zuehlke
Filed: April 30, 2025, 7:59 PM ET

Effective April 25, 2025, Scott Jordan resigned from employment as Chief Financial Officer of Zomedica Corp.

Earnings & guidance

2026-Q1 EPS reported $0.00 filing →

Materiality & sentiment trend

Max materiality 0.75 · Median 0.65 · Most common event earnings

5 positive 6 negative 8 neutral

source · ZOMDF on sec.gov